Impaired Notch4 activity elicits endothelial cell activation and apoptosis: implication for transplant arteriosclerosis. 2008

T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
INSERM U643, Nantes, F44000 France.

OBJECTIVE Notch signaling pathway controls key functions in vascular and endothelial cells (EC). However, little is known about the role of Notch in allografted vessels during the development of transplant arteriosclerosis (TA). This study investigated regulation of the Notch pathway on cardiac allograft arteriosclerosis and further examined its implication in EC dysfunction. RESULTS Here we show that, among Notch receptors, Notch2, -3, and -4 transcript levels were markedly downregulated in TA compared to tolerant and syngeneic allografts. TA correlates with high levels of tumor necrosis factor (TNF), transforming growth factor (TGF)beta, and IL10, which consistently decrease Notch4 expression in transplants and cultured ECs. We found that inhibition of Notch activity, reflected by both a reduced CBF1 activity and Hes1 expression, parallels the downregulation of Notch4 expression mediated by TNF in ECs. Notch4 and Hes1 knockdown enhances vascular cell adhesion molecule-1 expression and promotes EC apoptosis. Silencing Notch4 or Hes1 also drastically inhibits repair of endothelial injury. Overall, our results suggest that Notch4 and basal Notch activity are required to maintain EC quiescence and for optimal survival and repair in response to injury. CONCLUSIONS Together, our findings indicate that impaired Notch4 activity in graft ECs is a key event associated with TA by triggering EC activation and apoptosis.

UI MeSH Term Description Entries
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000072056 Transcription Factor HES-1 A basic-helix-loop-helix transcription factor that functions as a transcriptional repressor for genes transcribed by bHLH proteins. For example, it may negatively regulate MYOGENESIS by inhibiting MyoD1 and ASH1 proteins. It is also required for the stability of FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS and their localization to the cell nucleus in response to DNA DAMAGE. Hairy and Enhancer of Split 1 Protein,Hairy-Like Transcription Factor,HES-1, Transcription Factor,Hairy Like Transcription Factor,Transcription Factor HES 1,Transcription Factor, Hairy-Like
D000074562 Receptor, Notch4 A notch receptor and proto-oncogene protein characterized by a large extracellular domain that consists of 29 EPIDERMAL GROWTH FACTOR - like repeat sequences (EGF repeats) and five ANKYRIN REPEATS. It functions as a receptor for SERRATE-JAGGED PROTEINS and Delta1 (DLK1) protein to control cell fate determination. Notch-4 Protein,Notch-4 Receptor,Notch4 Protein,Notch4 Receptor,Notch 4 Protein,Notch 4 Receptor,Receptor, Notch-4
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic

Related Publications

T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
December 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
January 2020, Frontiers in physiology,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
July 2005, Proceedings of the National Academy of Sciences of the United States of America,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
January 2011, Xenotransplantation,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
January 2015, Atherosclerosis,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
March 2004, The Journal of biological chemistry,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
February 2011, Arteriosclerosis, thrombosis, and vascular biology,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
July 2000, Molecular medicine (Cambridge, Mass.),
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
January 2016, Frontiers in immunology,
T Quillard, and S Coupel, and F Coulon, and J Fitau, and M Chatelais, and M C Cuturi, and E Chiffoleau, and B Charreau
December 2005, The Journal of biological chemistry,
Copied contents to your clipboard!